<DOC>
	<DOCNO>NCT02972255</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multiple-ascending dose ( MAD ) study evaluate safety , tolerability pharmacokinetics ( PK ) RO7079901 combination RO7079901 meropenem healthy volunteer . The study consist three part ( Part I , II , III ) . At dose level/cohort , total 8 healthy volunteer randomize receive active study drug placebo 3:1 ratio .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics RO7079901 Combination RO7079901 With Meropenem Adult Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>Healthy male healthy female nonchildbearingpotential A Body Mass Index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) ( inclusive ) body weight least 45 kilogram ( kg ) screen Negative urine drug alcohol screen ( barbiturate , benzodiazepine , methadone , amphetamine , methamphetamine , opiate , cocaine , cannabinoids , cotinine , alcohol ) Nonsmokers , former smoker , smoke least 60 day prior screen Known history significant hypersensitivity severe allergic reaction betalactam antibiotic ( e.g. , cephalosporin , penicillin , carbapenems , monobactams ) History severe antibioticassociated superinfection like Clostridium difficile colitis and/or frequent fungal vaginal infection Concurrent history clinically significant cardiovascular , hepatic , renal , endocrine , gastrointestinal , respiratory , psychiatric , neurologic , and/or hematological disorder A history presence malignancy ( exception successfully treat basal cell carcinoma ) ; seizure , brain lesion significant neurological disease Donation blood ( loss blood ) great 500 milliliter ( mL ) within three month screen History Gilbert syndrome Any clinically significant concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk healthy volunteer study Positive test screen follow : Hepatitis A Virus Immunoglobulin M Antibody ( HAV IgM Ab ) , Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis C Virus Ribonucleic Acid Hepatitis C Virus Antibody ( HCV RNA HCVAb ) , Human Immunodeficiency Virus Antibody ( HIV Ab )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>